Check out Tuesday's after hours buzz: CSX, UAL, GIMO & more
- Investor's Business Daily•yesterday
Neurocrine's Tourette drug failed in a trial and the FDA approved a generic narcolepsy drug rivaling Jazz, and both stocks fell late.
The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.
NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||31.59 x 100|
|Day's Range||38.84 - 43.44|
|52 Week Range||31.25 - 55.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-28.93|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|